Endometrics

Executive Summary

Endometrics is a US-based diagnostics company addressing the critical unmet need for early endometriosis diagnosis. Currently, women face an average 8-year diagnostic delay due to reliance on invasive procedures and symptom tracking. Endometrics has developed a novel, non-invasive at-home test that analyzes menstrual blood for proprietary molecular biomarkers. This approach promises to accelerate diagnosis, reduce healthcare costs, and improve patient outcomes by enabling earlier intervention. The company's solution targets a large underserved market: endometriosis affects ~10% of reproductive-age women globally. With its first-of-its-kind home collection and molecular diagnostic platform, Endometrics is well-positioned to disrupt the current diagnostic pathway. Though still in development, the technology has the potential to become a standard of care if clinical validation is successful. The company operates in San Diego and was founded in 2017, but limited public information exists on funding or clinical milestones. Its success hinges on completing pivotal studies and securing regulatory clearance.

Upcoming Catalysts (preview)

• Q4 2026Pivotal Clinical Study Results65% success
• Q1 2027FDA Breakthrough Device Designation or Submission60% success
• Q3 2026Strategic Partnership with Women's Health Organization50% success